Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

NCT04672434 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Cancer
Solid Tumor

Interventions

DRUG: Sym021
DRUG: Sym024

Sponsor

Symphogen A/S